RSPH vs XLV

Key Takeaways

• RSPH offers equal-weight exposure to approximately 59 S&P 500 healthcare stocks, promoting broader diversification across mid-tier names compared to XLV's market-cap weighting that concentrates in mega-caps like Eli Lilly (LLY).
• XLV features a lower expense ratio of 0.08% versus RSPH's 0.40%, providing cost efficiency for long-term holders seeking benchmark-like healthcare sector performance.
• Both ETFs deliver 100% healthcare sector exposure but differ in sub-sector tilt: RSPH emphasizes balanced representation, while XLV overweight pharmaceuticals (around 36%) and biotech due to large-cap dominance.
• In recent months, RSPH has shown relative resilience with shallower YTD declines (-3.8% vs. XLV's -6.9%), benefiting from equal-weighting amid mega-cap healthcare volatility.
• XLV boasts superior liquidity with billions in AUM and high daily volume, ideal for institutional traders, while RSPH suits investors prioritizing reduced concentration risk.
• Risk profiles diverge: RSPH's higher beta (0.90) reflects greater sensitivity to broader healthcare moves, contrasting XLV's more stable 0.58 beta.

Introduction

Comparing RSPH and XLV illuminates key choices within healthcare ETFs, both tracking S&P 500 healthcare constituents but via contrasting weighting schemes. RSPH's equal-weight approach diversifies beyond dominant mega-caps, appealing to investors wary of concentration in firms like Eli Lilly. XLV's market-cap weighting mirrors the sector benchmark, capturing growth from top innovators while amplifying leader performance. Amid ongoing sector rotation toward defensive assets, macroeconomic pressures like interest rate shifts, and regulatory scrutiny on drug pricing, these ETFs offer alternative paths to healthcare exposure. This analysis highlights structural variances to aid portfolio positioning in a resilient yet volatile sector.

Invesco S&P 500® Equal Weight Health Care ETF (RSPH) Overview

The Invesco S&P 500® Equal Weight Health Care ETF (RSPH) is a passive ETF launched in November 2006, tracking the S&P 500 Equal Weight Health Care Index. This index includes all S&P 500 companies classified in the healthcare sector per the Global Industry Classification Standard (GICS), equally weighted to reduce mega-cap dominance. With approximately 59 holdings, RSPH maintains high diversification, where no single stock exceeds ~2.7% allocation. Top holdings include Centene (CNC, 2.65%), Humana (HUM, 2.45%), and UnitedHealth Group (UNH, 2.30%), emphasizing providers and services alongside pharma and devices.

Sector allocation is 100% healthcare, with balanced sub-exposure via quarterly rebalancing. The expense ratio stands at 0.40%, typical for equal-weight strategies. Distinguishing features include enhanced mid-cap tilt within large-caps, potentially amplifying returns during sector rotations away from top-heavy leaders. Liquidity is solid for retail investors, supported by NYSE Arca listing.

State Street® Health Care Select Sector SPDR® ETF (XLV) Overview

The State Street® Health Care Select Sector SPDR® ETF (XLV), inception December 1998, passively replicates the Health Care Select Sector Index—a market-cap-weighted benchmark of S&P 500 healthcare firms. Holding around 60 stocks, it concentrates exposure in leading names: Eli Lilly (LLY, 14.1%), Johnson & Johnson (JNJ, 10.5%), AbbVie (ABBV, 7.1%), UnitedHealth Group (UNH, 6.4%), and Merck (MRK, 5.2%). Top 10 holdings comprise ~60% of assets.

Sub-sector breakdown: pharmaceuticals (~36%), health care providers & services (19%), biotechnology (18%), equipment & supplies (17%), life sciences tools (9%). The ultra-low 0.08% expense ratio underscores cost leadership. Quarterly rebalancing aligns with the S&P index methodology. As a flagship sector SPDR, XLV excels in liquidity with massive AUM (~$37B) and high trading volume, suiting all investor scales.

Industry and Thematic Backdrop

The healthcare sector endures as a defensive pillar amid macroeconomic flux, buoyed by aging demographics, innovation in biotech/pharma, and steady demand for services. Yet, 2026 brings headwinds: policy shifts like the One Big Beautiful Bill Act (OBBBA) curbing Medicaid/ACA enrollment, drug pricing reforms, and prior authorization streamlining via CMS rules. Capital flows favor AI-driven efficiency, tech-enabled care, and behavioral health, while M&A accelerates in pharma/biotech amid favorable rates. Workforce shortages, inflation in wages/supplies, and regulatory scrutiny on private equity consolidation pose risks. Both ETFs benefit from sector resilience but navigate volatility from reimbursement changes and innovation cycles.

Performance and Positioning Comparison

Over recent months, RSPH has outperformed XLV on a relative basis, posting a milder YTD drawdown (-3.8%) versus XLV's steeper (-6.9%), attributable to equal-weighting buffering mega-cap pharma pullbacks amid pricing pressures and competition. In broader cycles, XLV's large-cap focus captures upside from blockbusters like GLP-1 drugs, though higher concentration elevates volatility during leader stumbles. RSPH's higher beta (0.90 vs. 0.58) signals amplified sector sensitivity, thriving in rotations toward mid-tier providers/services. Positioning-wise, XLV suits stability seekers; RSPH appeals for diversification amid cap-weighted froth. Both trail broader Health category averages recently, tied to elevated valuations and macro caution.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization (market cap), technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, empowering data-driven decisions across asset classes including sector ETFs like RSPH and XLV. Explore it today to uncover tailored healthcare insights.

Tickeron AI Verdict

Tickeron’s AI currently favors XLV with moderate conviction (60-70% probability in next market cycle). Its superior cost structure (0.08% expense ratio), massive liquidity, and benchmark alignment provide enduring edge, particularly amid mega-cap momentum in pharma/biotech. While RSPH's diversification shines in rotations, XLV's lower beta and structural efficiency position it better for consistent sector capture absent prolonged small-cap outperformance.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations